ConductScience.org, home

85,013 comparisons from ClinicalTrials.gov.

85,013 comparisons

Most participants first33,758 with no events in either group come last4,181 to 4,200 of 85,013

Show the results as
ComparisonWith the outcomeRisk difference, 95% intervalParticipantsTrial
Restrictive Fluids vs Liberal Fluids: deaths from any cause172 of 768

169 of 773

0.5 points

-3.6 to 4.7

1,541NCT03434028

Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis

3M Skin and Nasal Antiseptic vs Bactroban Nasal: Surgical Site Infections Occurring Within 12 Months of Surgical Procedure0 of 776

5 of 763

-0.7 points

-1.5 to -0.0

1,539NCT01313182

Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin

MK-4482 vs Placebo: deaths from any cause0 of 768

1 of 771

-0.1 points

-0.7 to 0.4

1,539NCT04939428

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

LY2605541 vs Glargine: serious adverse events105 of 1,003

73 of 535

-3.2 points

-6.8 to 0.2

1,538NCT01435616

A Study in Patients With Type 2 Diabetes Mellitus

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8259 of 1,027

121 of 510

1.5 points

-3.2 to 5.9

1,537NCT02940860

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8307 of 1,027

133 of 510

3.8 points

-1.0 to 8.4

1,537NCT02940860

Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease

Group 1: QIV-HD vs Group 2: QIV-SD: Number of Participants Reporting Unsolicited Adverse Events (AEs)190 of 772

172 of 761

2.0 points

-2.2 to 6.3

1,533NCT04024228

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Group 1: QIV-HD vs Group 2: QIV-SD: Number of Participants Reporting Immediate Unsolicited Adverse Events (AEs)2 of 772

1 of 761

0.1 points

-0.5 to 0.8

1,533NCT04024228

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Group 1 QIV-HD vs Group 2 QIV-SD: deaths from any cause2 of 772

0 of 761

0.3 points

-0.3 to 0.9

1,533NCT04024228

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

Group 1 QIV-HD vs Group 2 QIV-SD: serious adverse events17 of 772

21 of 761

-0.6 points

-2.2 to 1.0

1,533NCT04024228

Study to Assess the Immune Response and the Safety Profile of a High-Dose Quadrivalent Influenza Vaccine (QIV-HD) Compared to a Standard-Dose Quadrivalent Influenza Vaccine (QIV-SD) in Europeans Adults 60 Years of Age and Older

EEG Guided vs Usual Care: All-cause 30-day Mortality2 of 765

1 of 767

0.1 points

-0.5 to 0.8

1,532NCT03330236

EEG - Guided Anesthetic Care and Postoperative Delirium

Fluid Restriction Group vs Standard-care: Number of Participants With One or More Serious Adverse Reactions (SARs) to IV Crystalloids in the ICU.31 of 755

32 of 776

-0.0 points

-2.0 to 2.0

1,531NCT03668236

The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial

Fluid Restriction Group vs Standard-care: serious adverse events221 of 755

238 of 776

-1.4 points

-6.0 to 3.2

1,531NCT03668236

The Conservative vs. Liberal Approach to Fluid Therapy of Septic Shock in Intensive Care Trial

Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood) vs Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood): Number of Participants With Mortality From Any Cause201 of 771

192 of 760

0.8 points

-3.6 to 5.2

1,531NCT04704869

Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood) vs Early Cryoprecipitate + Massive Transfusion Protocol (RBCs, Plasma, Platelets, Whole Blood): deaths from any cause201 of 771

192 of 760

0.8 points

-3.6 to 5.2

1,531NCT04704869

Early Use of Cryoprecipitate With Major Hemorrhage Protocol (MHP) Activation

PROMUS vs PROMUS Element: serious adverse events237 of 762

238 of 768

0.1 points

-4.5 to 4.7

1,530NCT00823212

The PLATINUM Clinical Trial to Assess the PROMUS Element Stent System for Treatment of De Novo Coronary Artery Lesions

Molnupiravir vs Placebo: Percentage of Participants With ≥1 Adverse Event94 of 763

105 of 765

-1.4 points

-4.8 to 2.0

1,528NCT04939428

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

Molnupiravir vs Placebo: Percentage of Participants Discontinuing From Study Therapy Due to AE3 of 763

1 of 765

0.3 points

-0.4 to 1.0

1,528NCT04939428

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

MK-4482 vs Placebo: serious adverse events3 of 763

2 of 765

0.1 points

-0.6 to 0.9

1,528NCT04939428

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

Molnupiravir vs Placebo: Percentage of Participants (Regardless of SARS-CoV-2 in Baseline NP Swabs) Who Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 1478 of 763

103 of 764

-3.3 points

-6.5 to -0.0

1,527NCT04939428

Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)

Request

GET /api/comparisons/v1

Words from a trial's title, conditions or interventions, its outcome or its groups, or an NCT number.

An outcome counted in participants, the serious adverse events, or the deaths from any cause.

No key needed

Code

Show the call in
curl "https://conductscience.org/api/comparisons/v1?page=210"

Response

The first 2 of this page's 20 results. GET /api/comparisons/v1?page=210

{
  "data": {
    "total": 85013,
    "results": [
      {
        "id": "NCT03434028-deaths",
        "title": "Restrictive Fluids vs Liberal Fluids: deaths from any cause",
        "summary": "172 of 768 against 169 of 773; risk difference 0.5 points, 95% interval -3.6 to 4.7; NCT03434028, Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis",
        "record": "/library/comparisons/NCT03434028-deaths",
        "nct_id": "NCT03434028",
        "kind": "deaths",
        "participants": 1541,
        "risk_difference": {
          "value": 0.005329614057783538,
          "lower": -0.0361128315907545,
          "upper": 0.04677035695592194
        },
        "group_1": "172 of 768",
        "group_2": "169 of 773",
        "difference": "0.5 points",
        "interval": "-3.6 to 4.7",
        "trial_title": "Crystalloid Liberal or Vasopressors Early Resuscitation in Sepsis"
      },
      {
        "id": "NCT01313182-152c99a6",
        "title": "3M Skin and Nasal Antiseptic vs Bactroban Nasal: Surgical Site Infections Occurring Within 12 Months of Surgical Procedure",
        "summary": "0 of 776 against 5 of 763; risk difference -0.7 points, 95% interval -1.5 to -0.0; NCT01313182, Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin",
        "record": "/library/comparisons/NCT01313182-152c99a6",
        "nct_id": "NCT01313182",
        "kind": "outcome",
        "participants": 1539,
        "risk_difference": {
          "value": -0.00655307994757536,
          "lower": -0.015247724626428953,
          "upper": -0.00036165105609137476
        },
        "group_1": "0 of 776",
        "group_2": "5 of 763",
        "difference": "-0.7 points",
        "interval": "-1.5 to -0.0",
        "trial_title": "Prevention of Surgical Site Infections: Effectiveness of Nasal Povidone-Iodine and Nasal Mupirocin"
      }
    ],
    "no_events": 33758,
    "columns": [
      {
        "key": "title",
        "label": "Comparison"
      },
      {
        "key": "group_1",
        "label": "With the outcome",
        "under": "group_2"
      },
      {
        "key": "difference",
        "label": "Risk difference, 95% interval",
        "under": "interval"
      },
      {
        "key": "participants",
        "label": "Participants"
      },
      {
        "key": "nct_id",
        "label": "Trial",
        "under": "trial_title"
      }
    ],
    "order": "Most participants first",
    "kinds": {
      "all": 85013,
      "outcome": 33568,
      "serious-adverse-events": 31897,
      "deaths": 19548
    }
  },
  "release": "trial-comparisons-2026-03-23-0.1.0",
  "terms": [
    {
      "source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
      "license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "Freely available. Acknowledgement requested"
    },
    {
      "source": "ClinicalTrials.gov",
      "license": "none stated",
      "notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
      "short": "No license stated"
    }
  ],
  "next": "/api/comparisons/v1?page=211",
  "request_id": "OQpgxDps276MlaR5"
}

Ask about these results. The first 10 go in the prompt.

About this data
Holds
85,013 comparisons
From ClinicalTrials.gov. Counted 10 Nov 2026.
Release
23 Mar 2026
trial-comparisons-2026-03-23-0.1.0
Checked
20 of 20 review comparisons traced to ClinicalTrials.gov, and all 510,078 numbers calculated again apart from the builder agree
Access
Open
No account. 60 calls a minute from one address.

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

Genes

NCBI Gene

One gene with its proteins, patents, drugs, trials, grants and papers.

Trials

ClinicalTrials.gov

Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.

Sequences

Patent publications

Paste a sequence and see the patents that disclose it.

Opens sequences.conductscience.org

Drugs and targets

Open Targets

One drug with its targets, the diseases it is studied for, and the trials that name it, with their comparisons, papers and cognitive tests.

For software

Read Trial comparisons from software.

Every answer on this page is also JSON, under /api/comparisons/v1. No key.

GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome

Ask an assistant

  • In FOURIER, how did serious adverse events compare between evolocumab and placebo?
  • Which metformin trials reported deaths, and what was the risk difference?
  • What was the number needed to treat for HELIOS-B's composite outcome?
  • Which placebo-controlled heart failure trials had the most participants?